2nd Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$540,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2018 $540,000 Replaced
2nd Quarter - Amendment Jul 26, 2018 $540,000 Yes

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Orphan drug tax credit

LobbyistCovered position, as disclosed
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

HR 5340/S1390: Stronger Patents Act

LobbyistCovered position, as disclosed
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5340 (115th)

Trade (domestic/foreign) TRD

Committee on Foreign Investment in the United States (CFIUS) reform

LobbyistCovered position, as disclosed
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing

LobbyistCovered position, as disclosed
ENGEL BURNS —
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6 (115th), H.R. 2587 (115th)

Foreign Relations FOR

HR 4170: Disclosing Foreign Influence Act

LobbyistCovered position, as disclosed
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4170 (115th)

Medicare/Medicaid MMM

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D

LobbyistCovered position, as disclosed
ENGEL BURNS —
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4724 (115th), H.R. 6 (115th)

Pharmacy PHA

ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening

LobbyistCovered position, as disclosed
ENGEL BURNS —
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2368 (115th), S. 204 (115th), H.R. 878 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.